{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T13:05:22Z","timestamp":1785157522511,"version":"3.55.0"},"reference-count":135,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100002742","name":"Banaras Hindu University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002742","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001407","name":"Department of Biotechnology, Ministry of Science and Technology, India","doi-asserted-by":"publisher","award":["BT\/PR31156\/MED\/30\/2019"],"award-info":[{"award-number":["BT\/PR31156\/MED\/30\/2019"]}],"id":[{"id":"10.13039\/501100001407","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008812","name":"Defence Science and Technology Group","doi-asserted-by":"publisher","award":["IF230073"],"award-info":[{"award-number":["IF230073"]}],"id":[{"id":"10.13039\/501100008812","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochimica et Biophysica Acta (BBA) - Reviews on Cancer"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.bbcan.2025.189366","type":"journal-article","created":{"date-parts":[[2025,6,5]],"date-time":"2025-06-05T20:17:09Z","timestamp":1749154629000},"page":"189366","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["miRNA expression based modulation: A new paradigm for the treatment of chronic myeloid leukemia"],"prefix":"10.1016","volume":"1880","author":[{"given":"Sana","family":"Ansari","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malkhey","family":"Verma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.bbcan.2025.189366_bb0005","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1038\/cgt.2008.8","article-title":"Modulation of miRNA activity in human cancer: a new paradigm for cancer gene therapy?","volume":"15","author":"Tong","year":"2008","journal-title":"Cancer Gene Ther."},{"key":"10.1016\/j.bbcan.2025.189366_bb0010","doi-asserted-by":"crossref","first-page":"402","DOI":"10.3389\/fendo.2018.00402","article-title":"Overview of MicroRNA biogenesis, mechanisms of actions, and circulation","volume":"9","author":"O\u2019Brien","year":"2018","journal-title":"Front. Endocrinol."},{"key":"10.1016\/j.bbcan.2025.189366_bb0015","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2022.120437","article-title":"The role of microRNAs in the development, progression and drug resistance of chronic myeloid leukemia and their potential clinical significance","volume":"296","author":"Navabi","year":"2022","journal-title":"Life Sci."},{"issue":"15","key":"10.1016\/j.bbcan.2025.189366_bb0020","doi-asserted-by":"crossref","first-page":"12471","DOI":"10.3390\/ijms241512471","article-title":"Role of microRNAs in chronic lymphocytic leukemia","volume":"24","author":"Autore","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bbcan.2025.189366_bb0025","doi-asserted-by":"crossref","first-page":"4267","DOI":"10.2147\/CMAR.S174476","article-title":"Abnormal microRNA expression in the course of hematological malignancies","volume":"10","author":"Szymczyk","year":"2018","journal-title":"Cancer Manag. Res."},{"issue":"24","key":"10.1016\/j.bbcan.2025.189366_bb0030","doi-asserted-by":"crossref","first-page":"15524","DOI":"10.1073\/pnas.242606799","article-title":"Frequent deletions and down-regulation of micro- RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia","volume":"99","author":"Calin","year":"2002","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"32","key":"10.1016\/j.bbcan.2025.189366_bb0035","doi-asserted-by":"crossref","first-page":"11755","DOI":"10.1073\/pnas.0404432101","article-title":"MicroRNA profiling reveals distinct signatures in B cell chronic lymphocytic leukemias","volume":"101","author":"Calin","year":"2004","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"17","key":"10.1016\/j.bbcan.2025.189366_bb0040","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1056\/NEJMoa050995","article-title":"A MicroRNA signature associated with prognosis and progression in chronic lymphocytic leukemia","volume":"353","author":"Calin","year":"2005","journal-title":"N. Engl. J. Med."},{"issue":"7","key":"10.1016\/j.bbcan.2025.189366_bb0045","doi-asserted-by":"crossref","first-page":"3469","DOI":"10.3390\/ijms23073469","article-title":"MicroRNAs in leukemias: a clinically annotated compendium","volume":"23","author":"Turk","year":"2022","journal-title":"J. Mol. Sci."},{"issue":"12","key":"10.1016\/j.bbcan.2025.189366_bb0050","doi-asserted-by":"crossref","first-page":"5079","DOI":"10.1182\/blood-2007-02-071225","article-title":"Abnormal microRNA-16 locus with synteny to human 13q14 linked to CLL in NZB mice","volume":"109","author":"Raveche","year":"2007","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.bbcan.2025.189366_bb0055","doi-asserted-by":"crossref","first-page":"3363","DOI":"10.3390\/ijms25063363","article-title":"The screening of microRNAs in chronic myeloid leukemia: a clinical evaluation","volume":"25","author":"Wosniaki","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bbcan.2025.189366_bb0060","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.848199","article-title":"A systematic review of candidate miRNAs, its targeted genes and pathways in chronic myeloid leukemia-an integrated bioinformatical analysis","volume":"12","author":"Elias","year":"2022","journal-title":"Front. Oncol."},{"issue":"6","key":"10.1016\/j.bbcan.2025.189366_bb0065","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1158\/1078-0432.CCR-06-2320","article-title":"From mRNA metabolism to cancer therapy: chronic myelogenous leukemia shows the way","volume":"13","author":"Perrotti","year":"2007","journal-title":"Clin. Cancer Res."},{"issue":"1\u20132","key":"10.1016\/j.bbcan.2025.189366_bb0070","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.bcmd.2014.02.008","article-title":"ApoptomiRs expression modulated by BCR-ABL is linked to CML progression and imatinib resistance","volume":"53","author":"Ferreira","year":"2014","journal-title":"Blood Cells Mol. Dis."},{"issue":"1","key":"10.1016\/j.bbcan.2025.189366_bb0075","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1182\/blood-2002-08-2619","article-title":"HLA-matched related hematopoietic cell transplantation for chronic-phase CML using a targeted busulfan and cyclophosphamide preparative regimen","volume":"102","author":"Radich","year":"2003","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.bbcan.2025.189366_bb0080","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1056\/NEJMoa022457","article-title":"Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia","volume":"348","author":"O\u2019Brien","year":"2003","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.bbcan.2025.189366_bb0085","doi-asserted-by":"crossref","first-page":"207","DOI":"10.4103\/0971-5851.142036","article-title":"Current status of hematopoietic stem cell transplant in chronic myeloid leukemia","volume":"35","author":"Gupta","year":"2014","journal-title":"Ind. J. Med. Paediatr. Oncol."},{"issue":"8 Suppl A","key":"10.1016\/j.bbcan.2025.189366_bb0090","first-page":"8","article-title":"Fausel targeted chronic myeloid leukemia therapy: seeking a cure","volume":"13","author":"C.","year":"2007","journal-title":"J. Manag. Care Spec. Pharm."},{"key":"10.1016\/j.bbcan.2025.189366_bb0095","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1038\/s41392-023-01469-6","article-title":"Adverse effects of tyrosine kinase inhibitors in cancer therapy: pathophysiology, mechanisms and clinical management","volume":"8","author":"Shyam Sunder","year":"2023","journal-title":"Sig. Transduct. Target Ther."},{"issue":"3","key":"10.1016\/j.bbcan.2025.189366_bb0100","doi-asserted-by":"crossref","first-page":"154","DOI":"10.4103\/0971-5851.123711","article-title":"Chronic myeloid leukemia data from India","volume":"34","author":"Bansal","year":"2013","journal-title":"Ind. J. Med. Paediatr. Oncol."},{"issue":"1","key":"10.1016\/j.bbcan.2025.189366_bb0105","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1200\/JGO.2015.002667","article-title":"Chronic myeloid leukemia in India","volume":"3","author":"Ganesan","year":"2016","journal-title":"J. Glob. Oncol."},{"issue":"2","key":"10.1016\/j.bbcan.2025.189366_bb0110","doi-asserted-by":"crossref","first-page":"659","DOI":"10.3390\/ijms22020659","article-title":"Targeting abnormal hematopoietic stem cells in chronic myeloid leukemia and Philadelphia chromosome-negative classical myeloproliferative neoplasms","volume":"22","author":"Yung","year":"2021","journal-title":"Int. J. Mol. Sci."},{"issue":"4","key":"10.1016\/j.bbcan.2025.189366_bb0115","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1007\/s11010-022-04376-6","article-title":"Transport and metabolism of tyrosine kinase inhibitors associated with chronic myeloid leukemia therapy: a review","volume":"477","author":"Kumar","year":"2022","journal-title":"Mol. Cell. Biochem."},{"issue":"17","key":"10.1016\/j.bbcan.2025.189366_bb0120","doi-asserted-by":"crossref","first-page":"9779","DOI":"10.1073\/pnas.1630797100","article-title":"MicroRNAs and small interfering RNAs can inhibit mRNA expression by similar mechanisms","volume":"100","author":"Zeng","year":"2003","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"19","key":"10.1016\/j.bbcan.2025.189366_bb0125","doi-asserted-by":"crossref","first-page":"3582","DOI":"10.1016\/j.jmb.2013.03.007","article-title":"The role of miRNAs in regulating gene expression networks","volume":"425","author":"Gurtan","year":"2013","journal-title":"J. Mol. Biol."},{"issue":"2","key":"10.1016\/j.bbcan.2025.189366_bb0130","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.tibs.2004.12.007","article-title":"siRNA and miRNA: an insight into RISCs","volume":"30","author":"Tang","year":"2005","journal-title":"Trends Biochem. Sci."},{"key":"10.1016\/j.bbcan.2025.189366_bb0240","series-title":"Polycystic Kidney Disease [Internet]","article-title":"MicroRNAs and polycystic kidney disease","author":"Hajarnis","year":"2015"},{"issue":"7006","key":"10.1016\/j.bbcan.2025.189366_bb0135","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1038\/nature02873","article-title":"Mechanisms of gene silencing by double-stranded RNA","volume":"431","author":"Meister","year":"2004","journal-title":"Nature"},{"issue":"45","key":"10.1016\/j.bbcan.2025.189366_bb0140","doi-asserted-by":"crossref","first-page":"32773","DOI":"10.1074\/jbc.M705054200","article-title":"P68 RNA helicase unwinds the human let-7 microRNA precursor duplex and is required for let-7-directed silencing of gene expression","volume":"282","author":"Salzman","year":"2007","journal-title":"J. Biol. Chem."},{"issue":"8","key":"10.1016\/j.bbcan.2025.189366_bb0145","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.3324\/haematol.2009.020636","article-title":"Micro-RNA response to imatinib mesylate in patients with chronic myeloid leukemia","volume":"95","author":"Flamant","year":"2010","journal-title":"Haematology"},{"issue":"8","key":"10.1016\/j.bbcan.2025.189366_bb0150","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.3390\/genes15081054","article-title":"Gene variants in components of the microRNA processing pathway in chronic myeloid leukemia","volume":"15","author":"Chavaro-Francisco","year":"2024","journal-title":"Genes"},{"issue":"2","key":"10.1016\/j.bbcan.2025.189366_bb0155","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/S0092-8674(03)00801-8","article-title":"Functional siRNAs and miRNAs exhibit strand bias","volume":"115","author":"Khvorova","year":"2003","journal-title":"Cell"},{"issue":"3","key":"10.1016\/j.bbcan.2025.189366_bb0160","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/S1097-2765(02)00652-4","article-title":"RNAi in human cells: basic structural and functional features of small interfering RNA","volume":"10","author":"Chiu","year":"2002","journal-title":"Mol. Cell"},{"issue":"2","key":"10.1016\/j.bbcan.2025.189366_bb0165","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1261\/rna.2239606","article-title":"TarBase: a comprehensive database of experimentally supported animal microRNA targets","volume":"12","author":"Sethupathy","year":"2006","journal-title":"RNA (N.Y.)"},{"issue":"2","key":"10.1016\/j.bbcan.2025.189366_bb0170","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.molcel.2004.07.007","article-title":"Human Argonaute2 mediates RNA cleavage targeted by miRNAs and siRNAs","volume":"15","author":"Meister","year":"2004","journal-title":"Mol. Cell"},{"issue":"5","key":"10.1016\/j.bbcan.2025.189366_bb0175","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/j.molcel.2007.05.001","article-title":"Argonaute proteins: mediators of RNA silencing","volume":"26","author":"Peters","year":"2007","journal-title":"Mol. Cell"},{"issue":"1","key":"10.1016\/j.bbcan.2025.189366_bb0180","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1038\/nrm2085","article-title":"Illuminating the silence: understanding the structure and function of small RNAs","volume":"8","author":"Rana","year":"2007","journal-title":"Nat. Rev. Mol. Cell Biol."},{"issue":"3","key":"10.1016\/j.bbcan.2025.189366_bb0185","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pbio.0030085","article-title":"Principles of microRNA-target recognition","volume":"3","author":"Brennecke","year":"2005","journal-title":"PLoS Biol."},{"issue":"3","key":"10.1016\/j.bbcan.2025.189366_bb0190","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.tcb.2006.12.007","article-title":"Repression of protein synthesis by miRNAs: how many mechanisms?","volume":"17","author":"Pillai","year":"2007","journal-title":"Trends Cell Biol."},{"issue":"6","key":"10.1016\/j.bbcan.2025.189366_bb0195","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1038\/ncb1265","article-title":"Argonaute 2\/RISC resides in sites of mammalian mRNA decay known as cytoplasmic bodies","volume":"7","author":"Sen","year":"2005","journal-title":"Nat. Cell Biol."},{"issue":"11","key":"10.1016\/j.bbcan.2025.189366_bb0200","doi-asserted-by":"crossref","first-page":"4034","DOI":"10.1073\/pnas.0510928103","article-title":"MicroRNAs direct rapid deadenylation of mRNA","volume":"103","author":"Wu","year":"2006","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"5770","key":"10.1016\/j.bbcan.2025.189366_bb0205","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1126\/science.1122689","article-title":"Zebrafish MiR-430 promotes deadenylation and clearance of maternal mRNAs","volume":"312","author":"Giraldez","year":"2006","journal-title":"Science"},{"issue":"9","key":"10.1016\/j.bbcan.2025.189366_bb0210","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1101\/gad.1291905","article-title":"Pervasive regulation of Drosophila notch target genes by GY-box-, Brd-box-, and K-box-class microRNAs","volume":"19","author":"Lai","year":"2005","journal-title":"Genes Dev."},{"issue":"5","key":"10.1016\/j.bbcan.2025.189366_bb0215","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/ng1536","article-title":"Combinatorial microRNA target predictions","volume":"37","author":"Krek","year":"2005","journal-title":"Nat. Genet."},{"issue":"6","key":"10.1016\/j.bbcan.2025.189366_bb0220","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pbio.0020137","article-title":"Noise minimization in eukaryotic gene expression","volume":"2","author":"Fraser","year":"2004","journal-title":"PLoS Biol."},{"issue":"8","key":"10.1016\/j.bbcan.2025.189366_bb0225","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.0030146","article-title":"\u201cMyc\u2019ed messages\u201d: myc induces transcription of E2F1 while inhibiting its translation via a microRNA polycistron","volume":"3","author":"Coller","year":"2007","journal-title":"PLoS Genet."},{"issue":"4","key":"10.1016\/j.bbcan.2025.189366_bb0230","first-page":"26818","article-title":"Intronic microRNA (miRNA)","volume":"2006","author":"Lin","year":"2006","journal-title":"Biomed. Biotechnol."},{"issue":"7 Pt 1","key":"10.1016\/j.bbcan.2025.189366_bb0235","doi-asserted-by":"crossref","first-page":"2014","DOI":"10.1158\/1078-0432.CCR-05-1853","article-title":"Differentially regulated micro-RNAs and actively translated messenger RNA transcripts by tumor suppressor p53 in colon cancer","volume":"12","author":"Xi","year":"2006","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bbcan.2025.189366_bb0245","article-title":"The miR-203a regulatory network affects the proliferation of chronic myeloid leukemia K562 cells","volume":"9","author":"He","year":"2021","journal-title":"Front. Cell Dev. Biol."},{"issue":"D1","key":"10.1016\/j.bbcan.2025.189366_bb0250","doi-asserted-by":"crossref","first-page":"D155","DOI":"10.1093\/nar\/gky1141","article-title":"miRBase: from microRNA sequences to function","volume":"47","author":"Kozomara","year":"2019","journal-title":"Nucleic Acids Res."},{"issue":"4","key":"10.1016\/j.bbcan.2025.189366_bb0255","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/j.gde.2005.06.012","article-title":"MicroRNAs in vertebrate development","volume":"15","author":"Harfe","year":"2005","journal-title":"Curr. Opin. Genet. Dev."},{"issue":"24","key":"10.1016\/j.bbcan.2025.189366_bb0260","doi-asserted-by":"crossref","first-page":"2835","DOI":"10.4161\/cc.5.24.3579","article-title":"A new role for microRNA pathways: modulation of degeneration induced by pathogenic human disease proteins","volume":"5","author":"Bilen","year":"2006","journal-title":"Cell Cycle (Georgetown, Tex.)"},{"issue":"6","key":"10.1016\/j.bbcan.2025.189366_bb0265","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1038\/nbt0607-631","article-title":"MicroRNA gets down to business","volume":"25","author":"Mack","year":"2007","journal-title":"Nat. Biotechnol."},{"issue":"1","key":"10.1016\/j.bbcan.2025.189366_bb0270","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1101\/gr.082701.108","article-title":"Most mammalian mRNAs are conserved targets of microRNAs","volume":"19","author":"Friedman","year":"2009","journal-title":"Genome Res."},{"issue":"9","key":"10.1016\/j.bbcan.2025.189366_bb0275","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1038\/nrg2843","article-title":"The widespread regulation of microRNA biogenesis: function and decay","volume":"11","author":"Krol","year":"2010","journal-title":"Nat. Rev. Genet."},{"issue":"4","key":"10.1016\/j.bbcan.2025.189366_bb0280","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1038\/nrc1840","article-title":"Oncomirs - microRNAs with a role in cancer","volume":"6","author":"Esquela-Kerscher","year":"2006","journal-title":"Nat. Rev. Cancer"},{"issue":"7","key":"10.1016\/j.bbcan.2025.189366_bb0285","doi-asserted-by":"crossref","first-page":"2257","DOI":"10.1073\/pnas.0510565103","article-title":"A microRNA expression signature of human solid tumors defines cancer gene targets","volume":"103","author":"Volinia","year":"2006","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"5","key":"10.1016\/j.bbcan.2025.189366_bb0290","doi-asserted-by":"crossref","first-page":"570","DOI":"10.4161\/cc.7.5.5547","article-title":"MicroRNAs in malignant progression","volume":"7","author":"Ma","year":"2008","journal-title":"Cell Cycle (Georgetown Tex.)"},{"issue":"6","key":"10.1016\/j.bbcan.2025.189366_bb0295","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1093\/carcin\/bgs140","article-title":"microRNA involvement in human cancer","volume":"33","author":"Iorio","year":"2012","journal-title":"Carcinogenesis"},{"issue":"2","key":"10.1016\/j.bbcan.2025.189366_bb0300","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/S0092-8674(04)00045-5","article-title":"MicroRNAs: genomics, biogenesis, mechanism, and function","volume":"116","author":"Bartel","year":"2004","journal-title":"Cell"},{"issue":"4","key":"10.1016\/j.bbcan.2025.189366_bb0305","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/S1672-0229(08)60044-3","article-title":"A brief review on the mechanisms of miRNA regulation","volume":"7","author":"Cai","year":"2009","journal-title":"Genom. Proteom. Bioinform."},{"issue":"11","key":"10.1016\/j.bbcan.2025.189366_bb0310","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1038\/nrc1997","article-title":"MicroRNA signatures in human cancers","volume":"6","author":"Calin","year":"2006","journal-title":"Nat. Rev. Cancer"},{"issue":"7177","key":"10.1016\/j.bbcan.2025.189366_bb0315","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1038\/451414a","article-title":"Molecular biology: the expanding world of small RNAs","volume":"451","author":"Grosshans","year":"2008","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.bbcan.2025.189366_bb0320","doi-asserted-by":"crossref","first-page":"614","DOI":"10.3892\/or.2015.4456","article-title":"The roles of microRNAs in the pathogenesis and drug resistance of chronic myelogenous leukemia (review)","volume":"35","author":"Di Stefano","year":"2016","journal-title":"Oncol. Rep."},{"issue":"24","key":"10.1016\/j.bbcan.2025.189366_bb0325","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.2217\/bmm-2023-0575","article-title":"Dysregulation of miRNA expression in patients with chronic myelogenous leukemia at diagnosis: a systematic review","volume":"17","author":"Parsa-Kondelaji","year":"2023","journal-title":"Biomark. Med."},{"key":"10.1016\/j.bbcan.2025.189366_bb0330","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.3389\/fonc.2020.01544","article-title":"Comparison of microRNA expression profile in chronic myeloid leukemia patients newly diagnosed and treated by allogeneic hematopoietic stem cell transplantation","volume":"10","author":"Martins","year":"2020","journal-title":"Front. Oncol."},{"issue":"10","key":"10.1016\/j.bbcan.2025.189366_bb0335","doi-asserted-by":"crossref","first-page":"4399","DOI":"10.1182\/blood-2006-09-045104","article-title":"Expression of the miR-17-92 polycistron in chronic myeloid leukemia (CML) CD34+ cells","volume":"109","author":"Venturini","year":"2007","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.bbcan.2025.189366_bb0340","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1016\/j.cell.2010.01.007","article-title":"miR-328 functions as an RNA decoy to modulate hnRNP E2 regulation of mRNA translation in leukemic blasts","volume":"140","author":"Eiring","year":"2010","journal-title":"Cell"},{"issue":"7","key":"10.1016\/j.bbcan.2025.189366_bb0345","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1016\/j.leukres.2011.03.029","article-title":"MicroRNA-451 in chronic myeloid leukemia: miR-451-BCR-ABL regulatory loop?","volume":"35","author":"Lopotov\u00e1","year":"2011","journal-title":"Leuk. Res."},{"issue":"3","key":"10.1016\/j.bbcan.2025.189366_bb0350","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1007\/s12079-011-0139-x","article-title":"MicroRNAs 130a\/b are regulated by BCR-ABL and downregulate expression of CCN3 in CML","volume":"5","author":"Suresh","year":"2011","journal-title":"J. Cell Commun. Signal."},{"issue":"2 Pt B","key":"10.1016\/j.bbcan.2025.189366_bb0355","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/j.canlet.2014.10.006","article-title":"MiR-30e induces apoptosis and sensitizes K562 cells to imatinib treatment via regulation of the BCR-ABL protein","volume":"356","author":"Hershkovitz-Rokah","year":"2015","journal-title":"Cancer Lett."},{"issue":"2","key":"10.1016\/j.bbcan.2025.189366_bb0360","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.canlet.2015.02.031","article-title":"Restoration of miR-424 suppresses BCR-ABL activity and sensitizes CML cells to imatinib treatment","volume":"360","author":"Hershkovitz-Rokah","year":"2015","journal-title":"Cancer Lett."},{"issue":"9","key":"10.1016\/j.bbcan.2025.189366_bb0365","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1038\/cgt.2014.44","article-title":"The malignancy suppression role of miR-23a by targeting the BCR\/ABL oncogene in chronic myeloid leukemia","volume":"21","author":"Xishan","year":"2014","journal-title":"Cancer Gene Ther."},{"issue":"4","key":"10.1016\/j.bbcan.2025.189366_bb0370","first-page":"8881","article-title":"Restoration of miR-23a expression by chidamide sensitizes CML cells to imatinib treatment with concomitant downregulation of CRYAB","volume":"13","author":"Zhu","year":"2022","journal-title":"Bioengineering"},{"issue":"3","key":"10.1016\/j.bbcan.2025.189366_bb0375","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1111\/cas.12339","article-title":"Downregulation of miR-217 correlates with resistance of Ph(+) leukemia cells to ABL tyrosine kinase inhibitors","volume":"105","author":"Nishioka","year":"2014","journal-title":"Cancer Sci."},{"issue":"4","key":"10.1016\/j.bbcan.2025.189366_bb0380","article-title":"Inhibition of BCR\/ABL protein expression by miR-203 sensitizes for imatinib mesylate","volume":"8","author":"Li","year":"2013","journal-title":"PloS One"},{"issue":"1","key":"10.1016\/j.bbcan.2025.189366_bb0385","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/s12943-016-0518-2","article-title":"Clinical significance of microRNAs in chronic and acute human leukemia","volume":"15","author":"Yeh","year":"2016","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.bbcan.2025.189366_bb0390","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.2147\/DDDT.S66812","article-title":"Downregulated microRNA-148b in circulating PBMCs in chronic myeloid leukemia patients with undetectable minimal residual disease: a possible biomarker to discontinue imatinib safely","volume":"8","author":"Ohyashiki","year":"2014","journal-title":"Drug Des. Devel. Ther."},{"issue":"8","key":"10.1016\/j.bbcan.2025.189366_bb0395","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.1038\/leu.2012.65","article-title":"Targeting microRNA-30a-mediated autophagy enhances imatinib activity against human chronic myeloid leukemia cells","volume":"26","author":"Yu","year":"2012","journal-title":"Leukemia"},{"key":"10.1016\/j.bbcan.2025.189366_bb0400","doi-asserted-by":"crossref","first-page":"1173970","DOI":"10.3389\/fonc.2023.1173970","article-title":"Profiling of miRNAs and their interfering targets in peripheral blood mononuclear cells from patients with chronic myeloid leukaemia","volume":"13","author":"Wu","year":"2023","journal-title":"Front. Oncol."},{"key":"10.1016\/j.bbcan.2025.189366_bb0405","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.addr.2014.05.009","article-title":"In vivo delivery of miRNAs for cancer therapy: challenges and strategies","volume":"81","author":"Chen","year":"2015","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"3","key":"10.1016\/j.bbcan.2025.189366_bb0410","doi-asserted-by":"crossref","first-page":"373","DOI":"10.4161\/rna.7.3.11693","article-title":"Individual microRNAs (miRNAs) display distinct mRNA targeting \u201crules\u201d","volume":"7","author":"Wang","year":"2010","journal-title":"RNA Biol."},{"issue":"5","key":"10.1016\/j.bbcan.2025.189366_bb0415","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1097\/CCO.0000000000000657","article-title":"Targeting microRNA in hematologic malignancies","volume":"32","author":"Han","year":"2020","journal-title":"Curr. Opin. Oncol."},{"issue":"13","key":"10.1016\/j.bbcan.2025.189366_bb0420","doi-asserted-by":"crossref","first-page":"7156","DOI":"10.3390\/ijms22137156","article-title":"Dysregulation of miRNA in leukemia: exploiting miRNA expression profiles as biomarkers","volume":"22","author":"Anelli","year":"2021","journal-title":"Int. J. Mol. Sci."},{"issue":"4","key":"10.1016\/j.bbcan.2025.189366_bb0430","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1177\/0300985813502820","article-title":"MicroRNAs: history, biogenesis, and their evolving role in animal development and disease","volume":"51","author":"Bhaskaran","year":"2014","journal-title":"Vet. Pathol."},{"issue":"4","key":"10.1016\/j.bbcan.2025.189366_bb0435","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1373\/clinchem.2008.112805","article-title":"MicroRNAs: novel biomarkers for human cancer","volume":"55","author":"Bartels","year":"2009","journal-title":"Clin. Chem."},{"issue":"3","key":"10.1016\/j.bbcan.2025.189366_bb0440","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.jdermsci.2008.10.004","article-title":"MicroRNAs and the skin: tiny players in the body\u2019s largest organ","volume":"53","author":"Sand","year":"2009","journal-title":"J. Dermatol. Sci."},{"issue":"9","key":"10.1016\/j.bbcan.2025.189366_bb0445","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1261\/rna.032284.112","article-title":"Kinetic signatures of microRNA modes of action","volume":"18","author":"Morozova","year":"2012","journal-title":"RNA (New York, N.Y.)"},{"issue":"8","key":"10.1016\/j.bbcan.2025.189366_bb0540","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1016\/j.yexcr.2013.02.002","article-title":"miR-29b suppresses CML cell proliferation and induces apoptosis via regulation of BCR\/ABL1 protein","volume":"319","author":"Li","year":"2013","journal-title":"Exp. Cell Res."},{"issue":"3","key":"10.1016\/j.bbcan.2025.189366_bb0545","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.leukres.2012.12.003","article-title":"Decreased microRNA-30a levels are associated with enhanced ABL1 and BCR-ABL1 expression in chronic myeloid leukemia","volume":"37","author":"Liu","year":"2013","journal-title":"Leuk. Res."},{"issue":"6","key":"10.1016\/j.bbcan.2025.189366_bb0525","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/j.ccr.2008.04.018","article-title":"Genetic and epigenetic silencing of microRNA-203 enhances ABL1 and BCR-ABL1 oncogene expression","volume":"13","author":"Bueno","year":"2008","journal-title":"Cancer Cell"},{"key":"10.1016\/j.bbcan.2025.189366_bb0550","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1186\/1479-5876-9-197","article-title":"Methylation of miR-34a, miR-34b\/c, miR-124-1 and miR-203 in Ph-negative myeloproliferative neoplasms","volume":"9","author":"Chim","year":"2011","journal-title":"J. Transl. Med."},{"issue":"2","key":"10.1016\/j.bbcan.2025.189366_bb0480","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.gene.2014.03.049","article-title":"Down-regulation of miR-199b associated with imatinib drug resistance in 9q34.1 deleted BCR\/ABL positive CML patients","volume":"542","author":"Joshi","year":"2014","journal-title":"Gene"},{"key":"10.1016\/j.bbcan.2025.189366_bb0485","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/1476-4598-10-41","article-title":"Expression patterns of microRNAs associated with CML phases and their disease related targets","volume":"10","author":"Machov\u00e1 Pol\u00e1kov\u00e1","year":"2011","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.bbcan.2025.189366_bb0490","doi-asserted-by":"crossref","first-page":"127","DOI":"10.3389\/fphar.2017.00127","article-title":"The effects of antisense miRNA-20a alone or in combination with Imatinib on K562 cell proliferation","volume":"8","author":"Zhou","year":"2017","journal-title":"Front. Pharmacol."},{"issue":"1","key":"10.1016\/j.bbcan.2025.189366_bb0495","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1073\/pnas.0811466106","article-title":"A regulatory interplay between miR-27a and Runx1 during megakaryopoiesis","volume":"106","author":"Ben-Ami","year":"2009","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.bbcan.2025.189366_bb0500","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/1476-4598-8-69","article-title":"MicroRNA expression profiling in Imatinib-resistant chronic myeloid leukemia patients without clinically significant ABL1-mutations","volume":"8","author":"San Jos\u00e9-En\u00e9riz","year":"2009","journal-title":"Mol. Cancer"},{"issue":"12","key":"10.1016\/j.bbcan.2025.189366_bb0505","doi-asserted-by":"crossref","first-page":"1830","DOI":"10.1158\/1541-7786.MCR-08-0167","article-title":"Down-regulation of hsa-miR-10a in chronic myeloid leukemia CD34+ cells increases USF2-mediated cell growth","volume":"6","author":"Agirre","year":"2008","journal-title":"Mol. Cancer Res."},{"issue":"4","key":"10.1016\/j.bbcan.2025.189366_bb0510","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1111\/ijlh.12351","article-title":"Expression pattern of key microRNAs in patients with newly diagnosed chronic myeloid leukemia in chronic phase","volume":"37","author":"Fallah","year":"2015","journal-title":"Int. J. Lab. Hematol."},{"issue":"8","key":"10.1016\/j.bbcan.2025.189366_bb0515","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1182\/blood-2014-06-581926","article-title":"MicroRNA-486 regulates normal erythropoiesis and enhances growth and modulates drug response in CML progenitors","volume":"125","author":"Wang","year":"2015","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.bbcan.2025.189366_bb0520","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1182\/blood-2011-01-330704","article-title":"Circulating microRNAs let-7a and miR-16 predict progression-free survival and overall survival in patients with myelodysplastic syndrome","volume":"118","author":"Zuo","year":"2011","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.bbcan.2025.189366_bb0530","first-page":"289","article-title":"Modulating microRNAs in cancer: next-generation therapies. cancer","volume":"19","author":"Arghiani","year":"2021","journal-title":"Biol. Med."},{"key":"10.1016\/j.bbcan.2025.189366_bb0535","first-page":"748","article-title":"Up-regulation of miR-155 potentiates CD34+ CML stem\/progenitor cells to escape from the growth-inhibitory effects of TGF-\u00df1 and BMP signaling","volume":"20","author":"Mahdloo","year":"2021","journal-title":"EXCLI J."},{"key":"10.1016\/j.bbcan.2025.189366_bb0560","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s40164-016-0033-6","article-title":"miR-199b, a novel tumor suppressor miRNA in acute myeloid leukemia with prognostic implications","volume":"5","author":"Favreau","year":"2016","journal-title":"Exp. Hematol. Oncol."},{"key":"10.1016\/j.bbcan.2025.189366_bb0565","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2019.109413","article-title":"miR-96 acts as a tumor suppressor via targeting the BCR-ABL1 oncogene in chronic myeloid leukemia blastic transformation","volume":"119","author":"Huang","year":"2019","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.bbcan.2025.189366_bb0570","doi-asserted-by":"crossref","first-page":"5576059","DOI":"10.1155\/2021\/5576059","article-title":"The emerging roles of CCN3 protein in immune-related diseases","volume":"2021","author":"Peng","year":"2021","journal-title":"Mediators Inflamm."},{"issue":"2","key":"10.1016\/j.bbcan.2025.189366_bb0575","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/j.febslet.2010.12.027","article-title":"Involvement of miR-21 in resistance to daunorubicin by regulating PTEN expression in the leukaemia K562 cell line","volume":"585","author":"Bai","year":"2011","journal-title":"FEBS Lett."},{"issue":"10","key":"10.1016\/j.bbcan.2025.189366_bb0580","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1016\/j.leukres.2015.07.008","article-title":"Silencing of miR-21 sensitizes CML CD34+ stem\/progenitor cells to imatinib-induced apoptosis by blocking PI3K\/AKT pathway","volume":"39","author":"Wang","year":"2015","journal-title":"Leuk. Res."},{"issue":"8","key":"10.1016\/j.bbcan.2025.189366_bb0585","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.31557\/APJCP.2019.20.8.2379","article-title":"microRNA-21 expression as prognostic and therapeutic response marker in chronic myeloid leukaemia patients","volume":"20","author":"Mirza","year":"2019","journal-title":"Asian Pac. J. Cancer Prev."},{"issue":"12","key":"10.1016\/j.bbcan.2025.189366_bb0590","doi-asserted-by":"crossref","first-page":"2016","DOI":"10.3324\/haematol.2018.193086","article-title":"BCR-ABL1 mediated miR-150 downregulation through MYC contributed to myeloid differentiation block and drug resistance in chronic myeloid leukemia","volume":"103","author":"Srutova","year":"2018","journal-title":"Haematology"},{"issue":"1","key":"10.1016\/j.bbcan.2025.189366_bb0595","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1093\/labmed\/lmab040","article-title":"MiR-150 expression in chronic myeloid leukemia: relation to Imatinib response","volume":"53","author":"Habib","year":"2022","journal-title":"Lab. Med."},{"issue":"18","key":"10.1016\/j.bbcan.2025.189366_bb0600","doi-asserted-by":"crossref","first-page":"3631","DOI":"10.1182\/blood-2012-08-451765","article-title":"Foxp3+ T-regulatory cells require DNA methyltransferase 1 expression to prevent development of lethal autoimmunity","volume":"121","author":"Wang","year":"2013","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.bbcan.2025.189366_bb0605","doi-asserted-by":"crossref","first-page":"926","DOI":"10.3906\/biy-1705-66","article-title":"Determining expression of miRNAs that potentially regulate STAT5A and 5B in dasatinib-sensitive K562 cells","volume":"41","author":"Yilmaz","year":"2017","journal-title":"Turk. J. Biol."},{"issue":"3","key":"10.1016\/j.bbcan.2025.189366_bb0615","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0032834","article-title":"miR-181a post-transcriptionally downregulates oncogenic RalA and contributes to growth inhibition and apoptosis in chronic myelogenous leukemia (CML)","volume":"7","author":"Fei","year":"2012","journal-title":"PloS One"},{"issue":"3","key":"10.1016\/j.bbcan.2025.189366_bb0620","doi-asserted-by":"crossref","DOI":"10.1042\/BSR20171383","article-title":"Overexpression of miR-202 resensitizes imatinib resistant chronic myeloid leukemia cells through targetting Hexokinase 2","volume":"38","author":"Deng","year":"2018","journal-title":"Biosci. Rep."},{"key":"10.1016\/j.bbcan.2025.189366_bb0625","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/s13046-019-1502-7","article-title":"De-regulated STAT5A\/miR-202-5p\/USP15\/Caspase-6 regulatory axis suppresses CML cell apoptosis and contributes to Imatinib resistance","volume":"39","author":"Nie","year":"2020","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.bbcan.2025.189366_bb0630","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/1756-8722-6-16","article-title":"Epigenetic inactivation of the MIR129-2 in hematological malignancies","volume":"6","author":"Wong","year":"2013","journal-title":"J. Hematol. Oncol."},{"issue":"4","key":"10.1016\/j.bbcan.2025.189366_bb0635","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0019027","article-title":"Epigenetic inactivation of the miR-124-1 in haematological malignancies","volume":"6","author":"Wong","year":"2011","journal-title":"PloS One"},{"issue":"12","key":"10.1016\/j.bbcan.2025.189366_bb0640","doi-asserted-by":"crossref","first-page":"2760","DOI":"10.1111\/j.1582-4934.2011.01274.x","article-title":"Epigenetic inactivation of the hsa-miR-203 in haematological malignancies","volume":"15","author":"Chim","year":"2011","journal-title":"J. Cell. Mol. Med."},{"issue":"4","key":"10.1016\/j.bbcan.2025.189366_bb0645","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1093\/carcin\/bgq033","article-title":"Epigenetic inactivation of the miR-34a in hematological malignancies","volume":"31","author":"Chim","year":"2010","journal-title":"Carcinogenesis"},{"issue":"4","key":"10.1016\/j.bbcan.2025.189366_bb0450","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0035501","article-title":"Downregulation of miR-31, miR-155, and miR-564 in chronic myeloid leukemia cells","volume":"7","author":"Hershkovitz Rokah","year":"2012","journal-title":"PloS One"},{"issue":"7","key":"10.1016\/j.bbcan.2025.189366_bb0455","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.3390\/genes14071375","article-title":"miRNAs: potential as biomarkers and therapeutic targets for cancer","volume":"14","author":"Chakrabortty","year":"2023","journal-title":"Genes"},{"issue":"19","key":"10.1016\/j.bbcan.2025.189366_bb0460","first-page":"8468","article-title":"MiRNA-409-5p dysregulation promotes imatinib resistance and disease progression in children with chronic myeloid leukemia","volume":"23","author":"Liu","year":"2019","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"issue":"3","key":"10.1016\/j.bbcan.2025.189366_bb0465","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1007\/s00282-996-0269-4","article-title":"Additional translocation (9;12)(p13;q24.1) in newly diagnosed chronic myeloid leukemia: complete cytogenetic remission after interferon therapy","volume":"38","author":"Tertian","year":"1996","journal-title":"Hematol. Cell Ther."},{"issue":"6","key":"10.1016\/j.bbcan.2025.189366_bb0470","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1080\/10428194.2016.1243676","article-title":"miRNAs in chronic myeloid leukemia: small molecules, essential function","volume":"58","author":"Litwi\u0144ska","year":"2017","journal-title":"Leuk. Lymphoma"},{"issue":"10","key":"10.1016\/j.bbcan.2025.189366_bb0475","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1016\/j.leukres.2013.07.019","article-title":"Imatinib induces demethylation of miR-203 gene: an epigenetic mechanism of anti-tumor effect of imatinib","volume":"37","author":"Shibuta","year":"2013","journal-title":"Leuk. Res."},{"key":"10.1016\/j.bbcan.2025.189366_bb0650","article-title":"Circulating miRNAs can serve as potential diagnostic biomarkers in chronic myelogenous leukemia patients","volume":"16","author":"Keramati","year":"2021","journal-title":"Leuk. Res. Rep."},{"key":"10.1016\/j.bbcan.2025.189366_bb0655","doi-asserted-by":"crossref","first-page":"1209299","DOI":"10.3389\/fonc.2023.1209299","article-title":"Extracellular circulating miRNAs as potential non-invasive biomarkers in non-small cell lung cancer patients","volume":"13","author":"Raczkowska","year":"2023","journal-title":"Front. Oncol."},{"issue":"1","key":"10.1016\/j.bbcan.2025.189366_bb0670","first-page":"63","article-title":"miRNA-based therapeutic strategies","volume":"1","author":"Ishida","year":"2013","journal-title":"Curr. Anesthesiol. Rep."},{"issue":"11","key":"10.1016\/j.bbcan.2025.189366_bb0660","doi-asserted-by":"crossref","first-page":"2043","DOI":"10.1261\/rna.2414110","article-title":"MicroRNA sponges: progress and possibilities","volume":"16","author":"Ebert","year":"2010","journal-title":"RNA (New York, N.Y.)"},{"issue":"15","key":"10.1016\/j.bbcan.2025.189366_bb0665","doi-asserted-by":"crossref","first-page":"2332","DOI":"10.3390\/cells11152332","article-title":"MicroRNAs and their big therapeutic impacts: delivery strategies for cancer intervention","volume":"11","author":"Holjencin","year":"2022","journal-title":"Cells"},{"key":"10.1016\/j.bbcan.2025.189366_bb0680","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2021.111528","article-title":"MicroRNA: a signature for cancer progression","volume":"138","author":"Hussen","year":"2021","journal-title":"Biomed. Pharmacother."},{"issue":"4","key":"10.1016\/j.bbcan.2025.189366_bb0685","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1111\/cas.13965","article-title":"Development of miRNA-based therapeutic approaches for cancer patients","volume":"110","author":"Takahashi","year":"2019","journal-title":"Cancer Sci."},{"issue":"3","key":"10.1016\/j.bbcan.2025.189366_bb0690","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/nrd.2016.246","article-title":"MicroRNA therapeutics: towards a new era for the management of cancer and other diseases","volume":"16","author":"Rupaimoole","year":"2017","journal-title":"Nat. Rev. Drug Discov."},{"issue":"3","key":"10.1016\/j.bbcan.2025.189366_bb0695","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.3390\/ijms25031469","article-title":"Trials and tribulations of MicroRNA therapeutics","volume":"25","author":"Seyhan","year":"2024","journal-title":"Int. J. Mol. Sci."}],"container-title":["Biochimica et Biophysica Acta (BBA) - Reviews on Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304419X25001088?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304419X25001088?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T20:49:44Z","timestamp":1761943784000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0304419X25001088"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":135,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["S0304419X25001088"],"URL":"https:\/\/doi.org\/10.1016\/j.bbcan.2025.189366","relation":{},"ISSN":["0304-419X"],"issn-type":[{"value":"0304-419X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"miRNA expression based modulation: A new paradigm for the treatment of chronic myeloid leukemia","name":"articletitle","label":"Article Title"},{"value":"Biochimica et Biophysica Acta (BBA) - Reviews on Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbcan.2025.189366","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"189366"}}